摘要
目的研究Ｐ１６蛋白缺失与原发性肝癌发生发展的关系以及ＨＢＶ感染与Ｐ１６蛋白缺失的相关性．方法用免疫组化技术（ＬＳＡＢ法）检测７０例原发性肝癌组织标本中的Ｐ１６蛋白和ＨＢｓＡｇ．结果有６０６％（４０／６６）的肝细胞癌（ＨＣＣ）和７５０％（１／４）的胆管细胞癌（ＣＣＣ）Ｐ１６蛋白缺失；Ⅰ，Ⅱ，Ⅲ和Ⅳ级（按Ｅｄｍｏｎｄｓｏｎ标准）ＨＣＣＰ１６蛋白缺失率分别为００％（０／１），４４１％（１５／３４），８２１％（２３／２８）和６６７％（３／４），组间差异显著（Ｐ＜００５）．在有癌旁肝组织的４８例标本中，癌组织Ｐ１６蛋白阴性率（７２６％）明显高于癌旁肝组织（４１２％，Ｐ＜００５）．有６２５％（３０／４８）的ＨＣＣ癌旁肝组织ＨＢｓＡｇ阳性．ＨＢｓＡｇ阳性病例与阴性病例的Ｐ１６阴性率分别为７３３％（２２／３０）和６６７％（１２／１８），差异无显著性（Ｐ＞００５）．结论Ｐ１６蛋白缺失与原发性肝癌相关，与肝癌的恶性发展关系密切，可能对预后有重要影响．ＨＢＶ感染与Ｐ１６蛋白缺失无明显相关性．
IM To study the relationship between the deletion of P16 protein and the occurrence and development of primary carcinoma, and HBV infection. METHODS The P16 protein and HBsAg in primary liver carcinoma were detected by immunohistochemical technic in 70 cases of primary liver cancer. RESULTS P16 protein was undetactable in 606%(40/66) of hepatocellular carcinoma (HCC) and 750%(3/4) of cholangiocellular carcinoma (CCC). P16 protein deletion rates in HCC of grades Ⅰ,Ⅱ,Ⅲ and Ⅳ were 00%(0/1), 441%(15/34), 821%(23/28) and 667%(2/3), respectively (P<005). P16 protein deletion rate in the liver tissues near the cancer was lower (417%, 20/48) than that of cancer tissues (625%, 30/48), with significant difference (P<005). HBsAg was positive in 625%(30/48) of the liver tissues near the cancer. The difference of P16 protein deletion rate between the HBsAgpositive group (733%, 22/30) and the HBsAgnegative group (667%, 12/18) was not significant (P>005).CONCLUSION P16 protein deletion is closely related to primary liver carcinoma, particularly with its malignant development, and may be an important effect on prognosis. The correlation of HBV infection with P16 protein deletion is not significant.
关键词
肝癌
原发性
P16蛋白
乙型肝炎病毒
感染
liver neoplasms/metabolism
carcinoma, hepatocellular/metabolism
carrier proteins/metablism
hepatitis B/complications
